Browsing Tag
luspatercept
4 posts
Bristol Myers Squibb gets Reblozyl EC approval for anemia associated with NTD beta thalassemia
Bristol Myers Squibb (BMY) has secured full marketing authorization for Reblozyl (luspatercept) from the European Commission (EC) for…
March 4, 2023
EC approves Reblozyl for transfusion-dependent anemia in adults
Bristol Myers Squibb and Acceleron Pharma have secured approval from the European Commission (EC) for their jointly developed…
June 28, 2020
Celgene, Acceleron bag Reblozyl FDA approval for anemia in beta thalassemia
Reblozyl FDA approval : Celgene and Acceleron Pharma have bagged approval from the US Food and Drug Administration…
November 9, 2019
Bristol-Myers Squibb to acquire Celgene in $74bn pharma megadeal
Bristol-Myers Squibb has reached a definitive agreement to acquire Celgene Corporation in a monumental cash-and-stock deal worth approximately…
January 6, 2019